Filings reveal $220m to $750m in trades on US president’s behalf in first quarter of 2026, including securities linked to largest US companies
Hundreds of thousands of dollars was invested in Eli Lilly on Donald Trump’s behalf earlier this year, according to financial disclosures, as the US drugmaker benefited from his administration’s bid to expand access to blockbuster obesity treatments.
Ethics filings revealed several thousand trades on the US president’s behalf tied to stocks and bonds in the first quarter of 2026, with a cumulative value of between $220m and around $750m.
Continue reading...
TH
Source
This article was originally published by The Guardian and written by Anna Betts.
Read original article on The Guardian